Tissue Regenix Share Discussion Threads

[pennstreet] 15/1/2021 11:46

News must be very close

[channel pirate] 12/1/2021 17:01

Since the end of last year (2020) there has been regular 'dumpings' of 1,000,000 shares during most days, mixed in with some bigger chunky sells.

My Gut feeling is that as Gareth Jones left the company at the end of the year, and he had bought 24,000,000 shares @ 0.25p in that infamous fiasco of a placing he organised, then the sells could well be him, doubling his money in the process whilst the share price has been above 0.5p. As he has left the company, then there is no Director RNS required.

As I said guys, just my gut feeling

[cerrito] 11/1/2021 16:23

The Smith and Nephew Trading Statement this morning shows the headwinds the industry is facing.

[gnomemash94] 10/1/2021 23:13

Does this make sense?

Remember I could not work out the link between Parametric and Cellright. If you go back to my original link to the Parametric website (hxxps://parametricsmedical.com/va-contracted-items/ ) - would it make any sense that Cellright makes soemthink called Dermis on Demand for Parametric? How big is Parametric? Really odd that Cellright only make one think for them

Have copied the line from the Parametric page below - not sure what the numbers and stuff mean.

CellRight Technologies


Dermis


DOD15453


Dermis on Demand, 15mmx4.5mmx3mm, Freeze Dried


15mmx4.5mmx3mm


Irradiated


Freeze Dried

[ragnarr] 08/1/2021 18:19

I'm not going to complain if it does I tend to err on the side of caution

[hodhasharon] 08/1/2021 17:07

I disagree. I think we're going up quicker than you think. All the expansion plans are going well and the demand is there to take up anything we can produce.

Didn't the Woodford dumping land us down here in the first place? Not fundamentals.

[ragnarr] 08/1/2021 10:42

I concur - this isnt going to do an ARB overnight but expect 3/4p by year end - all imo

[ny boy] 08/1/2021 08:14

A good chart pattern, slow going north until this gathers stronger momentum, always good to get in early imo

Long term hold imo

[zxie] 07/1/2021 11:05

Rise up north

[ragnarr] 07/1/2021 10:46

Hmmm not so steady - something appears to be brewing

[ragnarr] 07/1/2021 09:53

Nice and steady build up to confirmation of phase 1 completion and increased capacity, then profit - share price has a long way to go yet imo.

[pennstreet] 07/1/2021 09:22

Ticking up nicely

[ragnarr] 06/1/2021 16:23

Good to see new board member putting money on the line :-)

[ragnarr] 06/1/2021 10:52

Looking to UK and EuropeDaniel Lee, Chief Executive Officer, Tissue Regenix Group, commented: "Our plan is to establish an initial distribution network for OrthoPure(R) XT and expand as procedural levels return. This will be a key product for the Group in Europe and highlights the need, and demand, for biologic solutions outside of the current US market. It is a testament to the work of our processing and commercial teams that we have secured distribution agreements and delivery of the product has remained on-track despite the challenges presented during 2020."

[gnomemash94] 05/1/2021 19:46

Cerrito - TRX is a US company (virtually 100% of sales) and the last thing it needs is someone in a different timezone delaying decision making. Also if it is eventually going to list on NASDAQ u need an American CFO who can talk the talk.

I don't care about a CFO or FD muppet who talks to the City all day long - that does not generate any value as people see through that. What you want is a CFO who speaks once a quarter or half year and says 'we beat forecasts'. Don't want to hear from him otherwise.

[ragnarr] 05/1/2021 17:17

The British Journal of Surgery produced a report at the end of May 2020 with the following results.ResultsThe best estimate was that 28?404?603 operations would be cancelled or postponed during the peak 12?weeks of disruption due to COVID?19 (2?367?050 operations per week). Most would be operations for benign disease (90·2 per cent, 25?638?922 of 28?404?603). The overall 12?week cancellation rate would be 72·3 per cent. Globally, 81·7 per cent of operations for benign conditions (25?638?922 of 31?378?062), 37·7 per cent of cancer operations (2?324?070 of 6?162?311) and 25·4 per cent of elective caesarean sections (441?611 of 1?735?483) would be cancelled or postponed. If countries increased their normal surgical volume by 20 per cent after the pandemic, it would take a median of 45?weeks to clear the backlog of operations resulting from COVID?19 disruption.ConclusionA very large number of operations will be cancelled or postponed owing to disruption caused by COVID?19. Governments should mitigate against this major burden on patients by developing recovery plans and implementing strategies to restore surgical activity safely.

[ragnarr] 05/1/2021 17:07

As of August 2020 there were 4.2m people waiting for consultant led elective surgery in the UK alone - pretty sure it will be worse now.

[cerrito] 05/1/2021 16:52

The next RNS on the board composition will presumably be the announcement of the new FD following the departure of Gareth Jones.I assume he/she will be based in the UK rather than the US as TRX is listed.
I note that the share price is riding high at a time when I assume elective procedures in hospitals in the US and UK and no doubt continental Europe are reduced.

[ragnarr] 05/1/2021 16:38

Difficult to comment without sounding like a blatant ramp but I am currently accumulating.

[gnomemash94] 04/1/2021 22:24

Ragnarr - many thanks for your writeup. I notice that you say that there is a potential _increase_ in revenue of about $36M pa. I think in my estimated valuation a few posts back I had assumed total revenue of $36M. If I remember correctly the company has basically done about 12-13M pounds of revenue so about $17M. So add in an increase of incremental $36M means nearer $53M at the end of phase 2.

I have just been looking over some slides I found on investormeetcompany and I think the company expected $19.8M capacity at the end of phase 1. Phase 2 adds about double again - so using that gets about $59M (19.8x 3).

Putting any of those numbers on 5.5x sales gets a market cap well near 240M pounds - would be pretty good even if we have to wait to 2022.

[b1inkers] 04/1/2021 14:51

Thanks alot Ragnarr.

£13.5m cash reserves as at June 2020, burn rate of £500k pcm. If phase 1 on track and on budget then breakeven point at, say, May 21 with ~£8m reserves before factoring in cost cutting. £5.1m expansion looks comfortable imho.

[ragnarr] 03/1/2021 20:42

Sorry cant find any real link betweenParsmetrics and Cellright/TRX - Only thing that comes to mind are TRX products used in tendon repair - possibly Derma pure or Matrix IQ Dermis Only a guess though.

[pennstreet] 03/1/2021 19:31

Great post ragnarr

[ragnarr] 03/1/2021 16:28

To answer your question The expansion programme started in July with phase 1 due for completion Jan/Feb so assuming phase 2 starts around then and completes within the 12 month plan, the potential stars early 2022. In the meantime phase 1 increases capacity by 50 percent and take the company into profit this year. Milestone year.This should give all the info you need re expansion :-)Expansion programme in San AntonioPart of the fundraise proceeds is being used to commence the facility expansion project in San Antonio. This programme has been divided into two phases, in order to deploy working capital in the most efficient manner and bring capacity on stream in a managed process to meet demand, while causing as little disruption to the current business as possible. Phase 1 of this programme commenced in July 2020, and is expected to take six months to fit out. However, it should be noted that, due to the osteoinductive testing required for the BioRinse product portfolio, sales will take a further three to four months to materialise.Given that TRX is now sourcing and processing more than double the number of tissue donors per month compared with a year ago, pressure has been put on its existing freezer storage capacity. To overcome this constraint, phase 1 of the reorganisation of San Antonio involves moving freezers into the new building. This will provide three times more freezer capacity and free up space in the existing facility for the installation of additional sterile packaging clean rooms.Phase 1 will result in the addition of two sterile packaging clean rooms within the existing facility. Once fully operational, these additional clean rooms are expected to increase the group's current BioRinse processing capacity by ca.50%. It is expected that completion of phase 1 would allow for the revenue generation potential required for the group to reach breakeven.TRX will also benefit from a $0.3m local University City grant to assist with implementation of the infrastructure for utilities, etc., needed to support this project.Phase 2 of the project will add up to 10 additional clean rooms in the new facility adjacent to the current manufacturing site. This phase is expected to take approximately 12 months to complete at a cost of $4.5m-$5.5m/ca.£4.0m.The total cost of the expansion project is expected to be $6.4m/£5.1m. However, once fully operational and validated, it is expected that the completed expansion project will increase the revenue generation potential by up to $36m p.a.

[gnomemash94] 03/1/2021 16:22

Remember I was confused about Parametric, Cellright and Tissue Regenix. Go onto the following page which mentions Cellright hxxps://parametricsmedical.com/va-contracted-items/ - what does that mean? U can get the same page from here - hxxps://parametricsmedical.com/?s=cellright - is Parametric a partner of Cellright or are there two companies called Cellright?